Cardiovasc Diabetol
-
Cardiovasc Diabetol · Sep 2015
Randomized Controlled Trial Multicenter StudyLong-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
The risk of cardiovascular morbidity and mortality is significantly increased in patients with diabetes; thus, it is important to determine whether glucose-lowering therapy affects this risk over time. Changes in cardiovascular risk markers were examined in patients with type 2 diabetes treated with exenatide twice daily (a glucagon-like peptide-1 receptor agonist) or glimepiride (a sulfonylurea) added to metformin in the EURopean EXenAtide (EUREXA) study. ⋯ NCT00359762, http://www.ClinicalTrials.gov.